This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
